

Special Issue

Molecular Mechanisms of Resistance to Cancer Therapies

Message from the Guest Editors

The persistent challenge of resistance to cancer therapies remains a significant obstacle in achieving durable clinical outcomes across cancer types. Understanding the molecular basis of both innate and acquired therapeutic resistance is critical for improving existing treatments and guiding the development of novel, more effective strategies to improve patient outcomes. We are pleased to invite you to contribute to a Special Issue that explores “Molecular Mechanisms of Resistance to Cancer Therapies”. This Special Issue aims to highlight recent advances in uncovering the cellular, molecular, and genetic underpinnings of resistance across chemotherapy, targeted therapy, immunotherapy, radiotherapy, and combination approaches. We welcome studies spanning in vitro, in vivo, and clinical settings, as well as computational and systems biology approaches that provide novel insights into resistance biology.

Guest Editors

Dr. Amancio Carnero

Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas, Avda. Manuel Siurot s/n, 41013 Seville, Spain

Dr. Rikki A.M. Brown

Harry Perkins Institute of Medical Research, University of Western Australia, Perth, WA 6009, Australia

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/249375

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)